Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-12-09
1999-11-30
Travers, Russell
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514114, 514649, A01N 3808, A01N 5700, A01N 3302
Patent
active
059944099
ABSTRACT:
The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.
REFERENCES:
patent: 3892824 (1975-07-01), Piper et al.
patent: 5424471 (1995-06-01), Kennedy et al.
patent: 5488042 (1996-01-01), Grdina
patent: 5567686 (1996-10-01), Grdina
patent: 5591731 (1997-01-01), Kennedy et al.
patent: 5846958 (1998-12-01), Capizzi et al.
patent: 5869338 (1999-02-01), Grdina
patent: 5891856 (1999-04-01), Grdnia
Aass et al., 1990, "Renal Function related to different treatment modalit for malignant germ cell tumors", Br. J. Cancer 62:842-846.
Akerfeldt, 1960, "Cysteamine S-Phosphoric Acid", Acta. Chem. Scand. 14;1980-1984.
Anand et al., 1993, "Newer insights into cisplatin nephrotoxicity", Ann. Pharmacother. 27:1519-1525.
Anderson's Pathology vol. 1, 8th Edition, 1985, pp. 1251, 734-735.
Borch, R.F. & Markman, M., 1989, "Biochemical Modulation of Cisplatin Toxicity", Pharmac. Ther. 41:371-380.
Cortese, 1943, Organic Syntheses pp. 91-93, Coll. vol. II, Blatt, Ed., John Wiley & Sons, Inc. NY, NY.
Daugaard et al., 1988, "Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose", Cancer Chemother. Pharmacol. 21:163-167.
DiPaolo, R. et al., 1997, "Amifostine and dose intense paclitaxel in patients with advanced malignancies", Cancer Therapeutics Proc. Am. Soc. Clin. Oncology 16:235a (abstract).
Doz et al., 1991, "Experimental Basis for Increasing the Therapeutic Index of Carboplatin in Brain Tumor Therapy by Pretreatment with WR-Compounds", Cancer Chemother. Pharmacol. 28:308.
du Bois et al., 1994, "Cisplatin and carboplatin induced acute, cummulative and chronic nephrotoxicity", Proc. Annu. Meet. Am. Assoc. Cancer Res. 35:A1475.
Finley et al., 1985, "Cisplatin nephrotoxicity: A summary of Preventative Interventions", Drug Intell. Clin. Pharm. 19:362-367.
Grdina, 1997, "Molecular Mechanisms in Cytoprotection and Chempprevention with ETHYOL.RTM. (amifostine)", Schering-Plough Pharmaceuticals pp. 2-26.
Grdina, J. & Sigdestad, C., 1989, "Radiation Protectors: The Unexpected Benefits", Drug Metab. Rev. 20(1):13-42.
Grdina et al., 1985, "The Radioprotector WR-1065 Reduces Radiation-Induced Mutations of the Hypoxanthine-Guanine Phosphoribosye Transferase Locus in V79 Cells", Carcinogenesis (London) 6:929-931.
Jordan et al., 1982, "Modulation of cis-platinum renal toxicity by the Radioprotective agent WR-2721", Exp. Mol. Pathol. 36:297.
Kemp et al., 1996, "Amifostine Pretreatment of Protection Against Cyclophosamide-induced and Cisplatin-induced Toxicities: Results of a Randomized Control Trial in Patient with Advanced Ovarian Cancer", J. Clin. Oncology 14:2101-2112.
List et al., 1996, "Amifostine Promotes Multilieage Hematopoiesisin Patient with Myelodysplastic Syndrome (MDS): Results of a Phase I/II Clinical Trial", Am. J. Hem. 1 (abstract).
List et al., 1996, "Amifostine Promotes Multilineage Hematopoiesis in Patients with Myelodysplastic Syndrome (MDS): Results of a Phase I/II Clinical Trial" (abstract), 8th Annual Meeting, American Society of Hematology, Orlando, FL.
List et al., 1996, "Amifostine Protects Primitive Hematopoietic Progenitors Against Chemotherapy Cytotoxicity", Semin. Oncol. 23(4) Supp. 8:58-63.
List et al., 1996, "Amifostine Stimulates Formation of Multipotent Progenitor and Generated Macroscopic Colonies in Normal and Myelodysplastic Bone Marrow", Proc. Am. Soc. Clin. Oncol. 15:449 (1403) [abstract].
Macleod et al., 1988, "The effect of cisplatin on renal function in patients with testicular tumors", Clin. Radiol. 39:190-192.
McGuire et al., 1996, "Cyclophosphamide and cisplatin compared with Paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer", N. Engl. J. Med. 334:1-6.
Meijer et al., 1983, "Influence of combination chemotherapy with cisdiammine chloroplatinum on renal function: Long term effects", Oncology 40:170-173.
Mollman, J.E. et al., 1988, "Cisplatin neuropathy: Risk factors, prognosis and protection by WR-2721", Cancer 61:2192-2195.
Nagy et al., 1986, "Protection Against cis-Diamminedichloroplatinum Cytotoxicity and Mutagenicity in V79 Cells by 2-[(Aminopropyl) amino] ethaniol", Cancer Research 46:1132-1135.
Physician's Desk Reference, 51st ed. 1997, pp. 485-486.
Physician's Desk Reference, 50th ed. 1996, pp. 716-717.
Physician's Desk Reference, 50th ed., Product Information, 1996, pp. 705-719.
Piper et al., 1966, "Hydrogen Bromide Cleavage of 3-Substituted 2-Oxazolidinones as a Synthetic Tool", Chem. Ind. (London) 2010.
Savoye, C. et al., 1997, "Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug Ethyol (Wr-2721), protect DNA against fast neutron--induced strand breakage", Int. J. Radiat. Biol. 71(2):193-202.
Stewart et al., 1997, "Association of Cisplatin Nephrotoxicity with Patient Characteristics and Cisplatin Administration Methods", Cancer Chemo. Pharmacol. 40:293-308.
Treskes et al., 1993, "WR2721 as a Modulator of Cisplatin-and Carboplatin-induced Side Effects in Comparison with other Chemoprotective Agents: A Molecular Approach", Cancer Chemother. Pharmacol. 33:93-106.
Treskes et al., 1992, "Effects of the Modulating Agent WR-2721 and its Main Metabolites on the Formation and Stability of Cisplatin-DNA Adducts in Vitro in Comparison to the Effects of Thiosulphate and Diethyldithiocarbonate", Biochem. Pharmacol. 43(5):1013-1019.
U.S. Bioscience, Inc., 1995, Product Information, p. 1-4.
Ward, J.F., 1983, "Chemical Aspects of DNA Radioprotection", Radioprotectors and Anticarcinogens, Academic Press, Inc., New York, pp. 73-85.
Washburn et al., 1976, "Prediction of the Effective Radioprotective Dose of WR-2721 in Humans Through an Interspecies Tissue Distribution Study", Radiat. Res. 66:100-105.
Yuhas, 1980, "Active versus Passive Absorption Kinetics as the Basis for Selective Protection of Normal Tissues by WR-2721", Cancer Res. 40:1519-1524.
Yuhas, 1979, "Differential Protection of Normal and Malignant Tissues Against the Cytotoxic Effects of Mechlorethamine", Cancer Treat. Rep. 63:971-976.
Jones et al., Toxicology 68(3):227-47 (1991).
Jones et al., Anticancer Research 9:1937-1942 (1989).
Trissel et al., Am. J. Health-Syst. Pharm. 52:2208-12 (Oct. 15, 1995).
Al-Sarraf et al., 1982, "Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study", Cancer Treat Rep 66:31-35.
Buntzel et al., 1998, "Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer", Ann Oncol 9:505-509.
Glover et al., 1987, "WR-2721 and High-Dose Cisplatin: An Active Combination in the Treatment of Metastic Melanoma", J. Clin Oncol 5:574-578.
Glover et al., 1986, "WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled Phase II trial", J. Clin Oncol 4:584-588.
Korst et al., 1997, "Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice", Brit J Cancer 75:1439-1445.
Korst et al., 1997, "Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors", Clin Cancer Res 3:697-703.
Schiller et al., 1996, "Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival", J Clin Oncol 14:1913-1921.
Ward, 1983, "Chemical Aspects of DNA Radioprotection", in Radioprotectors and Anticarcinogens, (Nygaard and Simic, eds.) Academic Press Inc., New York, pp. 73-85.
Physician's Desk Reference, 1998 edition, pp. 304, 500-502, 1998.
Physician's Desk Reference, 1999 edition, pp. 303, 513-515, 1999.
Bohuslavizki, K.H., et al., May 1997, "Protective Effect of Amifostine on Salivary Glands of Rabbits Treated With High Dose of Iodine-131," Scientific Abstracts of the 44.sup.th Annual Mee
Alberts David S.
Kaplan Edward H.
Stogniew Martin
The Arizona Board of Regents on behalf of the University of Ariz
Travers Russell
U.S. Bioscience, Inc.
LandOfFree
Methods for treatment of neuro--and nephro--disorders and therap does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of neuro--and nephro--disorders and therap, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of neuro--and nephro--disorders and therap will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1673368